1. SXTP reports increased demand for ARAKODA after a 6-month pilot. 2. Sales team expansion and GoodRx partnership planned for 2026. 3. New clinical sites for babesiosis treatment trials will be launched. 4. FDA feedback encourages further studies for breakthrough therapy designation. 5. Positive market trends point to robust growth opportunities for ARAKODA.
FAQ
Why Bullish?
The successful pilot program and expansion plans indicate strong demand and potential revenue growth. Historical precedents show market reactions to similar positive operational changes often yield upward price movements.
How important is it?
The article outlines significant strategic changes which directly affect SXTP's product trajectory and market positioning. Its focus on enhancing sales outreach and clinical research aligns closely with factors impacting stock performance.
Why Long Term?
The expansion initiatives and clinical trials could take time to materialize. Long-term potential hinges on improved sales strategies and successful regulatory feedback integration.
60 Degrees Pharmaceuticals Expands ARAKODA® Sales and Marketing Initiatives in 2026
On December 11, 2025, 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP), a company dedicated to developing innovative treatments for vector-borne diseases, announced its plans to enhance its sales and marketing efforts for ARAKODA®, a malaria prophylaxis medication. This decision follows promising results from a six-month commercial pilot, which indicated a growing demand for ARAKODA among healthcare providers.
Key Initiatives for ARAKODA Expansion
To build on the favorable pilot results, the Company intends to implement several strategic initiatives aimed at increasing market presence and driving ARAKODA sales in the upcoming year:
- Inside Sales Team Expansion: 60 Degrees Pharma plans to double the number of inside sales representatives to enhance outreach among prescribers, improve provider relationships, and offer better product education and support.
- GoodRx Partnership: The Company will collaborate with GoodRx to provide wider access to savings information at the point of sale, making it easier for patients and prescribers to find ARAKODA offers.
- Enhanced Digital Marketing Campaign: Building on earlier successes, the marketing team will optimize integrated digital campaigns to ensure sustained engagement and increased awareness among prescribers.
CEO’s Insight on Market Demand
Geoff Dow, PhD, the Chief Executive Officer, commented, “Results of our commercial pilot intended to measure market demand among prescribers demonstrated increasing demand trends. The investments we plan for 2026 reflect our commitment to expand reach, improve access, and support healthcare providers and patients with what we consider to be best-in-class malaria prevention.”
Clinical Trials and FDA Feedback
In addition to the marketing initiatives, the Company will initiate at least two new clinical sites for its ongoing babesiosis treatment trials. These studies include a randomized placebo-controlled trial (NCT06207370) and an expanded access study for high-risk patients (NCT06478641). This move comes in response to feedback from the U.S. Food and Drug Administration (FDA), which acknowledged that babesiosis qualifies as a serious illness and suggested that the Company resubmit its application for Breakthrough Therapy Designation.
The expansion of clinical sites may accelerate the enrollment of patients in these trials, thereby potentially expediting the availability of new treatment options.
About ARAKODA® (tafenoquine)
ARAKODA®, containing tafenoquine, is approved for malaria prophylaxis in the United States. Its safety profile was evaluated through five random controlled trials lasting up to six months. Since its approval for malaria prevention in 2018 and subsequent commercial launch in 2019, ARAKODA has been distributed through pharmaceutical networks and is available by prescription in retail pharmacies.
According to the Centers for Disease Control and Prevention, tafenoquine offers potential advantages in malaria prophylaxis due to its long half-life of approximately 16 days, allowing for less frequent dosing. However, it is not suitable for everyone, and important safety information must be reviewed before prescription.
Important Safety Information
- Contraindications: ARAKODA should not be prescribed to patients with G6PD deficiency or unknown G6PD status, those with a history of psychotic disorders, or individuals with known hypersensitivity to tafenoquine.
- Warnings: There is a risk of hemolytic anemia, requiring G6PD testing before prescription.
- Adverse Effects: Common adverse reactions include headache, dizziness, and gastrointestinal issues among others.
For more information or to report suspected adverse reactions, patients and healthcare professionals can contact 60 Degrees Pharmaceuticals, Inc. at 1-888-834-0225 or the FDA at 1-800-...